Abstract
Instrumental dilatation of the cervix prior to first trimester absorption may be difficult and source of complications. Pharmacological dilatation is proposed in a prospective random study using vaginal suppository containing 10 mg of 9-deoxo, 16-16 dimethyl, 9 methylene PGE2 (Meteneprost). Mean cervical dilatation, 3 hours after treatment, was significantly higher in the treated group (8.1 vs 6 mm) and additional dilatation was facilitated by cervical softening. Side effects occurred in most of the treated patients (uterine pain) but on a minor scale. This procedure may be considered as effective, safe and easy.
Publication types
-
Clinical Trial
-
English Abstract
-
Randomized Controlled Trial
MeSH terms
-
16,16-Dimethylprostaglandin E2 / administration & dosage
-
16,16-Dimethylprostaglandin E2 / analogs & derivatives
-
16,16-Dimethylprostaglandin E2 / therapeutic use*
-
Abortifacient Agents / therapeutic use*
-
Abortifacient Agents, Nonsteroidal / administration & dosage
-
Abortifacient Agents, Nonsteroidal / therapeutic use*
-
Abortion, Therapeutic*
-
Administration, Intravaginal
-
Adolescent
-
Adult
-
Female
-
Humans
-
Pregnancy
-
Pregnancy Trimester, First
-
Prostaglandins E, Synthetic / therapeutic use*
-
Random Allocation
-
Vacuum Curettage
Substances
-
Abortifacient Agents
-
Abortifacient Agents, Nonsteroidal
-
Prostaglandins E, Synthetic
-
meteneprost
-
16,16-Dimethylprostaglandin E2